Product news from 11/18/05 News Brief

Share this article:

The FDA approved Roche and Genentech's Tarceva (erlotinib) for a new indication as a treatment for patients with advanced pancreatic cancer. Tarceva has previously been approved by the FDA as a treatment for lung cancer.

Reliant Pharmaceuticals announced the FDA has approved its Supplemental New Drug Application for a new dosing regimen and label change for the fenofibrate therapy Antara (fenofibrate capsules) 43 mg and 130 mg. The new regimen enables patients to take Antara 130 mg capsules with or without food, increasing convenience for the 15% of adults in the U.S. with elevated triglycerides.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions